Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 induction, maintenance, and long-term extension study of batoclimab in generalized myasthenia gravis
jRCT2021230001Phase 3Active, not recruiting
- Sponsor
- Immunovant, Inc.
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, triple-blind trial of batoclimab in myasthenia gravis (MG) (3 arms), sponsored by Immunovant, Inc. Primary endpoint: Change from Period 1 baseline in MG-ADL score to Week 12 for AChRAb-positive participants. Started Sep 2023; status: active, not recruiting.
02
Drugs
batoclimab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on jRCT2021230001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021230001.